During an interview at the 2022 American Heart Association Scientific Sessions in Chicago, Michael A. Portman, MD, FAHA, Seattle Children's Hospital addressed how cardiac disease presents in pediatric vs adult patients.
During an interview at the 2022 American Heart Association Scientific Sessions in Chicago, the different types of cardiac diseases that present in pediatric patients vs adult patients were addressed by Michael A. Portman, MD, FAHA, director, Pediatric Cardiovascular Research, Center for Integrative Brain Research, and professor of pediatrics at Seattle Children's Hospital and the University of Washington in Seattle.
Transcript
How do treatments that address cardiac disease in children differ from those given to adult patients?
That's a really good question. The first issue is that children have different types of disease than adults. So in our particular study, we looked at several different types of heart disease. One was something called Kawasaki disease, which affects the coronary arteries and causes giant sacs, called aneurysms, that have a propensity for developing clots. That really doesn't occur in adults.
The second population is a population of patients who have single ventricle anatomy. So instead of 2 pumping chambers of the heart, there's only 1 and you have to do a surgical procedure called a Fontan procedure to assist 1 ventricle in performing the work of both. So those patients are also at high risk for clotting.
Those patients do grow up, they all grew up to be adults, but these are different diseases than adults get, who have, for instance, atrial fibrillation or myocardial infarction or coronary artery sclerosis—they're totally different types of diseases. We do have patients who have heart failure, and that is similar to adults, but treatment for adults is not necessarily the best treatment for children.
Exploring Racial, Ethnic Disparities in Cancer Care Prior Authorization Decisions
October 24th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the October 2024 issue of The American Journal of Managed Care® that explored prior authorization decisions in cancer care by race and ethnicity for commercially insured patients.
Listen
Sarcoma Care: Biomarker Advancements Shape the Future
October 24th 2024At the regional Institute for Value-Based Medicine® event in Boston, Vinayak Venkataraman, MD, medical oncologist at Dana-Farber Cancer Institute and Harvard Medical School, was a panelist for the discussion, “Recent Advancements in Identifying Predictive Biomarkers for Sarcomas."
Read More
The Latest in New and Emerging Therapies in Schizophrenia: Dr Megan Ehret
October 22nd 2024In addition to Cobenfy being approved for schizophrenia, there are other drugs with novel mechanisms being studied that may mean combination therapies or, at least, more options for patients in the future.
Read More